"On the "Conversations with Tyler" podcast, host Tyler Cowen asked Altman for his "nuttiest view" about his health. The OpenAI CEO said that his level of health consciousness depended on his workload. "When I was less busy, I was more disciplined on health-related stuff," Altman said. "I kind of ate healthy. I didn't drink that much. I worked out a lot.""
"Altman also experimented: "I once ended up in a hospital for trying semaglutide before it was cool," he said. Altman didn't expand or explain the specific reason for the hospitalization, like dehydration or exhaustion. Semaglutide, sold under brand names like Ozempic and Wegovy, is a GLP-1 drug prescribed for obesity and type 2 diabetes treatment. A side effect of GLP-1 drugs is that they curb appetite, triggering weight loss."
Sam Altman tried semaglutide and ended up hospitalized; the specific reason was not disclosed. He leads a busy life, is a first-time father, and has traveled globally to support AI infrastructure, which has reduced attention to personal health. He currently eats junk food and exercises less. Semaglutide (brands Ozempic, Wegovy) is a GLP-1 medication for obesity and type 2 diabetes that suppresses appetite and can cause weight loss. Off-label use among people without obesity or diabetes has increased; high-profile users include Elon Musk and other tech CEOs.
Read at Business Insider
Unable to calculate read time
Collection
[
|
...
]